U.S. Court of Appeals Upholds Validity of Lilly's Alimta Compound Patent
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the District of Delaware that the company's compound patent for Alimta^® (pemetrexed) is valid. The compound patent provides protection for Alimta in the U.S. through January of 2017.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.